Accendra Health, Inc. reports developments in home-based healthcare products, technology and services delivered through the Apria and Byram Healthcare brands. The company connects patients, providers and insurers across diabetes supplies, sleep health, respiratory care, wound care, urology, ostomy and related patient support categories.
News for ACH centers on quarterly results, guidance, continuing-operations performance after the completed sale of the Products & Healthcare Services business, NYSE ticker changes, debt reduction, maturity extension and other balance-sheet actions tied to its home healthcare platform.
Accendra Health (NYSE: ACH) received a continued-listing noncompliance notice from the NYSE on October 27, 2026, without immediate delisting.
The standard requires average market capitalization of at least $50.0 million over 30 consecutive trading days and stockholders’ equity of at least $50.0 million. The company intends to submit a business plan to regain compliance within 18 months of receiving the notice.
Accendra Health (ACH) plans to release its third-quarter 2026 financial results on November 5, 2026, after New York Stock Exchange trading ends. The company will host an investor and analyst conference call that day at 5:00 p.m. EST, with a simultaneous live webcast on its Investor Relations website. A webcast replay will be available afterward.
Accendra Health (NYSE: ACH) received a notice of noncompliance with the NYSE’s minimum share price requirement on October 6, 2026.
Its Class A common stock averaged less than $1.00 per share over 30 consecutive trading days. The company has six months after receiving the notice to regain compliance and intends to respond within ten business days affirming its intent to cure the deficiency. Accendra intends to consider alternatives, including a reverse stock split if necessary, subject to stockholder approval no later than its next annual meeting, anticipated in May 2027.
The notice does not trigger immediate delisting. Shares continue trading on the NYSE, subject to other continued listing standards, and the notice does not affect business, operations or SEC reporting requirements.
Accendra Health (ACH) appointed board member Kenneth Gardner-Smith as its next President and Chief Executive Officer, with the transition expected early in the fourth quarter of 2026, succeeding retiring CEO Edward A. Pesicka.
Gardner-Smith has served on the board since March 2022 and is currently CEO of Veritas Veterinary Partners, where he led a strategy reset and executive rebuild that produced double-digit average quarterly revenue growth and margin expansion. His prior experience includes 13 years at DaVita, nine as a senior P&L owner managing $1.5 billion in operations and supporting teams across more than 3,000 facilities in 13 countries. He has been part of Accendra’s long-term succession planning and is expected to focus on growth in higher-margin categories, operating efficiency, and continued investment.
Pesicka will remain CEO until the handover, then retire from the board and continue as an advisor, and the company expects no operational disruption. Accendra also named Scott Lloyd as its first Chief Commercial Officer, effective October 5, 2026, a new role uniting commercial strategy, sales, and provider and payor partnerships under one leader reporting to the CEO.
Accendra Health (ACH) updated investors on capital allocation and CEO succession plans. The company decided not to implement a previously contemplated at-the-market equity issuance program, stating it was never intended as a liquidity source and its cancellation will not affect results of operations or published guidance.
According to Accendra Health, liquidity is supported by increasing cash collections, progress on resolving payor collection issues, and an undrawn $300 million revolving credit facility, which it does not expect to use except for working capital fluctuations. The company closed the sale of one non-core asset in Q3 and expects a second to close by year-end, for combined cash proceeds of about $45 million with de minimis impact on Adjusted EBITDA. The board expects to name a successor to CEO Mr. Pesicka by mid-September 2026, ahead of his planned retirement by end-2026, with him remaining as CEO until the transition and then serving in an advisory role.
Accendra Health (NYSE: ACH) announced that its board adopted a Section 382 Rights Agreement, called a Tax Asset Preservation Plan, effective August 10, 2026. The plan is intended to help preserve the company’s net operating loss carryforwards (NOLs) and other tax attributes by discouraging ownership changes under Section 382 of the Internal Revenue Code.
The plan aims to deter any person or group from acquiring 4.9% or more of Accendra Health’s outstanding common stock. If an “ownership change” occurs, holders of rights (other than the triggering person) may purchase common shares at a 50% discount or the company may exchange each right for one share. The plan is scheduled to remain in effect until August 10, 2029, unless terminated earlier. Accendra Health will also host its previously announced second quarter 2026 earnings conference call on August 10, 2026 at 8:00 a.m. ET, with access via toll-free and webcast options.
Accendra Health (NYSE: ACH) reported second quarter 2026 continuing-operations net revenue of $613.2 million, down from $681.9 million in 2Q25, with a GAAP loss from continuing operations of $89.1 million versus $83.8 million a year earlier. Adjusted EBITDA was $60.1 million (2Q25: $96.6 million) and free cash flow was -$25.1 million (2Q25: $15.2 million). The company reduced outstanding debt by $385 million and said it has eliminated well over $125 million of annualized operating expense tied to a large commercial payor exit.
For full-year 2026, Accendra Health guides to net revenue of $2.45–$2.55 billion, adjusted EBITDA of $300–$320 million, and free cash flow of breakeven to slightly positive. CEO Edward A. Pesicka has informed the board of his intention to retire by the end of 2026.
Accendra Health (NYSE: ACH) announced that President and CEO Edward A. Pesicka plans to retire by the end of 2026 and will leave the Board of Directors before year-end 2026. The Board has an established succession planning process and has already identified potential CEO candidates, and will now conduct a comprehensive search.
According to the company, Pesicka may serve in an advisory role after retirement to support a smooth transition. Management highlighted his role in stabilizing the company, expanding PPE production during the pandemic, executing the divestiture of Owens & Minor, a balance sheet optimization transaction, and the transformation into Accendra Health. The company also reminded investors of its second-quarter 2026 earnings conference call on August 10, 2026, at 8:00 a.m. ET.
Accendra Health (ACH) announced leadership changes in Information Technology and Procurement to support its strategy as a pure play home-based care organization. Nicholas (Nick) Piecora was promoted in May to Senior Vice President & Chief Information Officer, reporting to President & CEO Edward Pesicka. Agnes Ansay has been appointed Vice President & Chief Procurement Officer, effective immediately, reporting to Executive Vice President & CFO Jonathan Leon.
According to Accendra Health, Piecora will focus on leveraging technology and automation to enhance home-based care, customer experience, and operational performance. Ansay will lead the Procurement organization, drawing on more than 10 years of global procurement leadership across large, complex enterprises.
Accendra Health (NYSE: ACH) plans to release its second quarter 2026 financial results on Monday, August 10, 2026, before NYSE trading begins. The company will host an investor conference call at 8:00 a.m. EDT, with phone and webcast access plus a replay available.